Fausto Berti

497 total citations
33 papers, 399 citations indexed

About

Fausto Berti is a scholar working on Immunology, Pediatrics, Perinatology and Child Health and Molecular Biology. According to data from OpenAlex, Fausto Berti has authored 33 papers receiving a total of 399 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Immunology, 12 papers in Pediatrics, Perinatology and Child Health and 9 papers in Molecular Biology. Recurrent topics in Fausto Berti's work include Biosimilars and Bioanalytical Methods (16 papers), Pharmaceutical studies and practices (12 papers) and Genomics, phytochemicals, and oxidative stress (9 papers). Fausto Berti is often cited by papers focused on Biosimilars and Bioanalytical Methods (16 papers), Pharmaceutical studies and practices (12 papers) and Genomics, phytochemicals, and oxidative stress (9 papers). Fausto Berti collaborates with scholars based in Italy, New Zealand and United States. Fausto Berti's co-authors include Patrizia Hrelia, Carmela Fimognari, Giorgio Cantelli‐Forti, Michael Nüsse, Renato Iori, G.C. Folco, Steven R. Feldman, Giorgio Forti, Eric Guenzi and Richard Kay and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of the New York Academy of Sciences and Cellular and Molecular Life Sciences.

In The Last Decade

Fausto Berti

26 papers receiving 379 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fausto Berti Italy	12	245	98	85	83	69	33	399
Narendra Joshi India	9	165 0.7×	96 1.0×	51 0.6×	34 0.4×	29 0.4×	17	363
Vinitha Ramanath Pai India	11	139 0.6×	27 0.3×	113 1.3×	17 0.2×	39 0.6×	28	397
Charles desBordes United States	14	424 1.7×	29 0.3×	31 0.4×	37 0.4×	54 0.8×	21	599
Sylwia Borska Poland	12	233 1.0×	19 0.2×	40 0.5×	45 0.5×	33 0.5×	19	412
Nantiga Virgona Japan	18	336 1.4×	18 0.2×	64 0.8×	94 1.1×	32 0.5×	34	611
Janaína Fernandes Brazil	11	323 1.3×	33 0.3×	58 0.7×	31 0.4×	87 1.3×	22	494
Paban K. Agrawala India	15	293 1.2×	38 0.4×	31 0.4×	43 0.5×	134 1.9×	45	647
Lisa A. Shamon United States	8	232 0.9×	19 0.2×	35 0.4×	81 1.0×	91 1.3×	10	431
Anila Dwivedi India	16	205 0.8×	161 1.6×	68 0.8×	17 0.2×	23 0.3×	32	549
Yuan‐Wan Sun United States	17	345 1.4×	36 0.4×	77 0.9×	73 0.9×	44 0.6×	49	671

Countries citing papers authored by Fausto Berti

Since Specialization

Citations

This map shows the geographic impact of Fausto Berti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fausto Berti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fausto Berti more than expected).

Fields of papers citing papers by Fausto Berti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fausto Berti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fausto Berti. The network helps show where Fausto Berti may publish in the future.

Co-authorship network of co-authors of Fausto Berti

This figure shows the co-authorship network connecting the top 25 collaborators of Fausto Berti. A scholar is included among the top collaborators of Fausto Berti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fausto Berti. Fausto Berti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rai, Masna, et al.. (2025). Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study. BioDrugs. 40(1). 135–149.

Rai, Masna, et al.. (2025). Assessment of comparative efficacy between candidate biosimilar AVT05 and reference golimumab. Zeitschrift für Gastroenterologie. 63.

Jaśkiewicz, Łukasz, et al.. (2025). A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, pharmacodynamic, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (60 mg/mL) in healthy male adults. Expert Opinion on Investigational Drugs. 34(6). 527–537. 1 indexed citations

Wynne, Chris, et al.. (2025). Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group Study. BioDrugs. 40(1). 121–133.

Berti, Fausto, et al.. (2023). 42601 Assessment of Bioequivalence Between Candidate Biosimilar AVT04 and Reference Ustekinumab. Journal of the American Academy of Dermatology. 89(3). AB123–AB123. 2 indexed citations

Wynne, Christopher, et al.. (2023). A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults. Expert Opinion on Investigational Drugs. 32(5). 417–427. 10 indexed citations

Feldman, Steven R., et al.. (2023). 42913 Assessment of Therapeutic Equivalence Between Candidate Biosimilar AVT04 and Reference Ustekinumab. Journal of the American Academy of Dermatology. 89(3). AB124–AB124. 2 indexed citations

Richter, Kathleen, et al.. (2023). Ex vivo comparative immunogenicity assessment (EVCIA) to determine relative immunogenicity in chronic plaque psoriasis in participants receiving Humira® or undergoing repeated switches between Humira® and AVT02. PubMed. 4(1). ltad029–ltad029. 1 indexed citations

Berti, Fausto, et al.. (2022). Joint analysis of PK and immunogenicity outcomes using factorization model − a powerful approach for PK similarity study. BMC Medical Research Methodology. 22(1). 264–264. 1 indexed citations

10.

Feldman, Steven R., Grażyna Pulka, Külli Kingo, et al.. (2021). Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study. BioDrugs. 35(6). 735–748. 22 indexed citations

11.

Berti, Fausto, et al.. (2013). Build quality of groundwater wells and contamination problems. SHILAP Revista de lepidopterología. 2(2). 1 indexed citations

12.

Fimognari, Carmela, Fausto Berti, Michael Nüsse, Giorgio Forti, & Patrizia Hrelia. (2005). In vitro Antitumor Activity of Cyanidin-3-O-β-Glucopyranoside. Chemotherapy. 51(6). 332–335. 17 indexed citations

13.

Fimognari, Carmela, Fausto Berti, Giorgio Cantelli‐Forti, & Patrizia Hrelia. (2005). Effect of sulforaphane on micronucleus induction in cultured human lymphocytes by four different mutagens. Environmental and Molecular Mutagenesis. 46(4). 260–267. 31 indexed citations

14.

Fimognari, Carmela, Luca Sangiorgi, Michael Nüsse, et al.. (2005). A mutated p53 status did not prevent the induction of apoptosis by sulforaphane, a promising anti-cancer drug. Investigational New Drugs. 23(3). 195–203. 15 indexed citations

15.

Fimognari, Carmela, Fausto Berti, Renato Iori, Giorgio Cantelli‐Forti, & Patrizia Hrelia. (2005). Micronucleus formation and induction of apoptosis by different isothiocyanates and a mixture of isothiocyanates in human lymphocyte cultures. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 582(1-2). 1–10. 24 indexed citations

16.

Fimognari, Carmela, Fausto Berti, Michael Nüsse, Giorgio Cantelli‐Forti, & Patrizia Hrelia. (2004). Induction of apoptosis in two human leukemia cell lines as well as differentiation in human promyelocytic cells by cyanidin-3-O-β-glucopyranoside. Biochemical Pharmacology. 67(11). 2047–2056. 64 indexed citations

17.

Fimognari, Carmela, Fausto Berti, Giorgio Cantelli‐Forti, & Patrizia Hrelia. (2004). Effect of cyanidin 3‐O‐β‐glucopyranoside on micronucleus induction in cultured human lymphocytes by four different mutagens. Environmental and Molecular Mutagenesis. 43(1). 45–52. 18 indexed citations

18.

Fimognari, Carmela, Michael Nüsse, Fausto Berti, et al.. (2004). Isothiocyanates as novel cytotoxic and cytostatic agents: molecular pathway on human transformed and non-transformed cells. Biochemical Pharmacology. 68(6). 1133–1138. 44 indexed citations

19.

Fimognari, Carmela, Michael Nüsse, Fausto Berti, et al.. (2003). Sulforaphane Modulates Cell Cycle and Apoptosis in Transformed and Non‐transformed Human T Lymphocytes. Annals of the New York Academy of Sciences. 1010(1). 393–398. 34 indexed citations

20.

Fimognari, Carmela, Michael Nüsse, Fausto Berti, et al.. (2002). Cyclin D3 and p53 mediate sulforaphane-induced cell cycle delay and apoptosis in non-transformed human T lymphocytes. Cellular and Molecular Life Sciences. 59(11). 2004–2012. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact